News Hub

LPC Snapshot - June 2022

LPC Snapshot - June 2022
ISCT 2022 Meeting Highlight - Non-Malignant Applications of CAR T

Medhat Askar, MD, PhD, MSHPE, F(ACHI), FRCPath
Transplant Immunology, COVID-19 & Cell Processing Laboratories
Baylor University Medical Center
Clinical Professor of Pathology & Lab Medicine, Texas A&M College of Medicine
Director of Clinical Services, NMDP/BTM
Consultant, Memorial Sloan Kettering Cancer Center
New York, NY, USA

Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary therapeutic approach that has been effective in treating multiple relapsed/refractory diseases.  More recent advances in therapeutic applications of CAR-T cells include non-malignant diseases such as autoimmune and infectious diseases as well as prevention of allograft rejection in organ transplantation.  This feature explores the session at ISCT 2022 San Francisco focused on non-malignant applications of CAR-T.  

Read Article